Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$57.09
-1.2%
$59.88
$54.48
$94.93
$7.73B1.191.16 million shs1.41 million shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$75.55
-3.4%
$70.73
$55.30
$94.99
$3.76B0.39675,269 shs660,605 shs
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$155.96
$155.74
$93.34
$156.22
$10.30B0.55656,912 shsN/A
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$12.59
-4.4%
$12.80
$11.06
$32.66
$1.02B1.15970,843 shs692,979 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$237.37
-2.7%
$264.08
$148.00
$310.00
$9.44B0.47454,604 shs377,311 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
-1.16%-3.40%-6.12%-21.53%-17.80%
Haemonetics Corporation stock logo
HAE
Haemonetics
-3.57%-1.69%+5.62%+25.99%-13.22%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00%0.00%0.00%0.00%0.00%
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
-4.40%-6.64%-1.87%-25.90%-57.05%
Penumbra, Inc. stock logo
PEN
Penumbra
-2.61%-5.26%-6.11%-12.87%+32.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.9447 of 5 stars
4.35.00.04.12.22.51.9
Haemonetics Corporation stock logo
HAE
Haemonetics
4.9147 of 5 stars
4.53.00.04.32.21.72.5
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
N/AN/AN/AN/AN/AN/AN/AN/A
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
4.1548 of 5 stars
2.91.00.04.02.11.72.5
Penumbra, Inc. stock logo
PEN
Penumbra
4.8205 of 5 stars
4.42.00.03.72.72.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.62
Moderate Buy$94.0064.65% Upside
Haemonetics Corporation stock logo
HAE
Haemonetics
3.00
Buy$97.3028.79% Upside
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00
N/AN/AN/A
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
1.78
Reduce$18.6347.93% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$305.0728.52% Upside

Current Analyst Ratings Breakdown

Latest GMED, PEN, IART, HAE, and HRC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$95.00
7/9/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$90.00
7/9/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$320.00 ➝ $285.00
6/26/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$87.00
6/25/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/10/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/27/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
5/27/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
5/20/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$100.00 ➝ $100.00
5/12/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$80.00 ➝ $68.00
5/9/2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$100.00 ➝ $80.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$2.51B3.08$6.58 per share8.68$30.40 per share1.88
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.36B2.67$6.96 per share10.85$16.34 per share4.62
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$3.02B3.41$9.29 per share16.79$28.56 per share5.46
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$1.61B0.61$4.25 per share2.96$20.03 per share0.63
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B7.70$2.81 per share84.48$29.99 per share7.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$102.98M$1.3442.6014.171.687.39%10.52%8.56%8/5/2025 (Estimated)
Haemonetics Corporation stock logo
HAE
Haemonetics
$167.68M$3.3122.8214.991.2712.32%26.37%9.22%8/14/2025 (Estimated)
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/A
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
-$6.94M-$0.38N/A5.040.73-1.78%12.12%4.58%8/4/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$1.06223.9347.382.173.41%11.14%8.40%7/29/2025 (Estimated)

Latest GMED, PEN, IART, HAE, and HRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.79N/AN/AN/A$738.91 millionN/A
8/4/2025Q2 2025
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$0.43N/AN/AN/AN/AN/A
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81N/AN/AN/A$327.37 millionN/A
5/8/2025Q1 2025
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.74$0.68-$0.06$0.54$629.74 million$598.12 million
5/8/2025Q4 2025
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.22$1.24+$0.02$1.17$329.38 million$330.60 million
5/5/2025Q1 2025
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
$0.43$0.41-$0.02-$0.33$381.17 million$382.65 million
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$0.960.62%N/A25.81%N/A
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.45
2.72
Haemonetics Corporation stock logo
HAE
Haemonetics
1.12
1.62
0.99
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.97
1.38
1.05
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
0.81
1.21
0.72
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.30
3.68

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Corporation stock logo
HAE
Haemonetics
99.67%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
76.45%
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
84.78%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.51%
Haemonetics Corporation stock logo
HAE
Haemonetics
1.84%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.69%
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
3.54%
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,300135.38 million110.32 millionOptionable
Haemonetics Corporation stock logo
HAE
Haemonetics
3,02348.04 million47.16 millionOptionable
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
10,00066.05 million65.59 millionOptionable
Integra LifeSciences Holdings Corporation stock logo
IART
Integra LifeSciences
4,39677.71 million74.96 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50038.73 million37.10 millionOptionable

Recent News About These Companies

Oversold Conditions For Penumbra (PEN) - Nasdaq

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Globus Medical stock logo

Globus Medical NYSE:GMED

$57.09 -0.71 (-1.23%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$57.10 +0.00 (+0.01%)
As of 07/11/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Haemonetics stock logo

Haemonetics NYSE:HAE

$75.55 -2.62 (-3.35%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$74.70 -0.85 (-1.13%)
As of 07/11/2025 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Hill-Rom stock logo

Hill-Rom NYSE:HRC

Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.

Integra LifeSciences stock logo

Integra LifeSciences NASDAQ:IART

$12.59 -0.58 (-4.40%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$12.57 -0.02 (-0.16%)
As of 07/11/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Penumbra stock logo

Penumbra NYSE:PEN

$237.37 -6.50 (-2.67%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$237.92 +0.55 (+0.23%)
As of 07/11/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.